详情页

当前位置：首页 > 详情页

Real-world outcomes of second-line osimertinib for advanced NSCLC patients with EGFR mutation in China

文献详情

资源类型：

WOS体系：

收录情况： ◇ SCIE ◇ CPCI(ISTP)

作者：

机构： [1]Shanghai Lung Cancer Center, Shanghai Chest Hospital, Shanghai Jiao Tong University,Shanghai, China [2]Oncology Department, The First Affiliated Hospital ofZhengzhou University, Zhengzhou, China [3]Oncology Department, Henan ProvincialPeople’s Hospital, Zhengzhou, China [4]Oncology Department, Shanghai Ruijin -Ammed Cancer Centre, Shanghai, China [5]Oncology, Liaoning Cancer Hospital &Institute, Shenyang, China [6]Oncology Department, Shanxi Da Hospital, Taiyuan,China [7]Oncology Department, Suzhou Fourth People’s Hospital/ Suzhou MunicipalHospital, Suzhou, China [8]Oncology Department, Henan Cancer Hospital/AffiliatedCancer Hospital of Zhengzhou University, Zhengzhou, China [9]Oncology Department,The Fourth Hospital of Hebei Medical University - North Gate, Shijiazhuang, China [10]Oncology Department, Beijing Tuberculosis and Thoracic Tumor Research Institute,Beijing, China [11]Medical Oncology Department, Shanghai Chest Hospital, ShanghaiJiao Tong University, Shanghai, China

出处：

ISSN：

语种：

WOS：

中科院分区：

出版当年[2022]版：

大类 | 1 区

医学

小类 | 1 区肿瘤学

最新[2025]版：

大类 | 1 区

医学

小类 | 1 区肿瘤学

JCR分区：

出版当年[2022]版：

Q1 ONCOLOGY

最新[2024]版：

Q1 ONCOLOGY

影响因子： 65.4 最新[2024版] 46.8 最新五年平均 50.5 出版当年[2022版] 32.4 出版当年五年平均 51.769 出版前一年[2021版] 56.7 出版后一年[2023版]

第一作者：

第一作者机构： [1]Shanghai Lung Cancer Center, Shanghai Chest Hospital, Shanghai Jiao Tong University,Shanghai, China

推荐引用方式(GB/T 7714)：

APA：

MLA：